...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Evaluation of Serratia Peptidase in Acute or Chronic Inflammation of Otorhinolaryngology Pathology: A Multicentre, Double-Blind, Randomized Trial versus Placebo
【24h】

Evaluation of Serratia Peptidase in Acute or Chronic Inflammation of Otorhinolaryngology Pathology: A Multicentre, Double-Blind, Randomized Trial versus Placebo

机译：沙耳菌肽酶在耳鼻喉科病理学的急性或慢性炎症中的评估：一项多中心，双盲，随机试验与安慰剂比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The efficacy and tolerability of Serratia peptidase were evaluated in a multicentre, double-blind, placebo-controlled study of 193 subjects suffering from acute or chronic ear, nose or throat disorders. Treatment lasted 7–8 days, with the drug or placebo being administered at a rate of two tablets three times a day. After 3–4 days' treatment, significant symptom regression was observed in peptidase-treated patients. There was also a significant reduction in symptoms after 7 – 8 days for patients in both treatment groups but the response was more marked in those patients receiving the active drug. Statistical comparison between the two groups confirmed the greater efficacy and rapid action of the peptidase against all the symptoms examined at both stages. Tolerance was found to be very good and similar for both groups. It is concluded that Serratia peptidase has anti-inflammatory, anti-oedemic and fibrinolytic activity and acts rapidly on localized inflammation.
机译：在多中心，双盲，安慰剂对照研究中，对193名患有急性或慢性耳，鼻或咽喉疾病的受试者进行了评估，对沙雷氏菌肽酶的功效和耐受性进行了评估。治疗持续7-8天，药物或安慰剂每天两次服用两次，每次3次。治疗3-4天后，经肽酶治疗的患者出现了明显的症状消退。两个治疗组的患者在7-8天后症状也显着减轻，但接受活性药物的患者的反应更为明显。两组之间的统计比较证实了肽酶对两个阶段检查的所有症状均具有更高的功效和更快的作用。两组的耐受性非常好，相似。结论是沙雷氏菌肽酶具有抗炎，抗血液和纤溶活性，并且对局部炎症具有快速作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号